The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Destiny Pharma jumps on positive nasal gel study

Mon, 29th Mar 2021 09:59

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

----------

AIM - WINNERS

----------

Destiny Pharma PLC, up 27% at 203.20 pence, 12-month range 29.1p-250p. 12-month high was hit earlier on Monday. The biotechnology firm reports data which found its nasal gel may be effective in preventing post-surgical bacterial infections. Results from a Phase 2b trial of XF-73 meet the primary efficacy endpoint. It shows a 99.5% decline in staphylococcus aureus bacterial nasal carriage, a "very effective reduction by accepted clinical measures", Destiny says. Compared to a placebo, it shows a greater than 99% reduction.

----------

Europa Metals Ltd, up 13% at 12.98p, 12-month range 4.25p-30.00p. The Australian mining projects developer reports a widened interim pretax loss but says there does not currently appear to be any material impact on the company or any significant uncertainties as a result of the coronavirus pandemic. Posts pretax loss of AUD1.7 million - about USD1.3 million - for the six months to the end of 2020, compared to AUD1.4 million loss a year earlier.

----------

Blackbird PLC, up 10% at 26.95p, 12-month range 9.5p-29.65p. The developer and seller of cloud video editing platforms says BT has chosen it for "ultra-fast and sustainable" cloud native video editing and publishing. Blackbird will work in conjunction with Pete Harvey, BT's head of digital media content operations. Harvey will use Blackbird to access and edit multiple live broadcast streams of sports and other content for the "fast" production of assets for downstream distribution to over the top and video on demand channels.

----------

AIM - LOSERS

----------

RA International Group PLC, down 16% at 41.24p, 12-month range 27.2p-72.5p. The remote site services provider notes a further escalation in hostile activity in the Cabo Delgado province, northern Mozambique, near to where the company's operations are based. Says security concerns, compounded by the pandemic and extreme weather, have led to delays to the overall energy related project in the region and to the suspension of its contract to build and operate an 1,800-person camp, where an extension of the initial two-year tenancy contract is under negotiation. "Given the escalation in hostilities in the area in recent days, the directors of the company now expect there will be further delays in the project that are likely to impact on the overall financial performance of the company in the current financial year. This impact is expected, at the current time, to be up to USD10 million of revenue, which the directors expect will now be recognised in a later financial period," says Chief Executive Soraya Narfeldt.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
15 Nov 2021 20:37

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

IN BRIEF: Destiny Pharma's Morgan to step down from board in March

Read more
18 Oct 2021 15:12

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

TRADING UPDATES: Mind Gym revenue recovers; Dispersion buys Accru

Read more
18 Oct 2021 09:25

Destiny Pharma upbeat on recent study into mupirocin alternative

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Monday that a major US hospital-based clinical trial lent "strong support" for the potential of its 'XF-73' nasal product as an alternative to mupirocin in the treatment of Staphylococcus aureus infections.

Read more
27 Sep 2021 10:58

IN BRIEF: Destiny Pharma unveils new XF-73 skin infection drug project

IN BRIEF: Destiny Pharma unveils new XF-73 skin infection drug project

Read more
27 Sep 2021 10:10

Destiny Pharma's China partner starts new XF-73 programme

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced on Monday that its China regional partner and investor, China Medical System Holdings (CMS), is establishing a new programme with 'XF-73' targeting the prevention and treatment of superficial skin infections caused by bacteria.

Read more
9 Sep 2021 11:33

EARNINGS UPDATES: STV, Chaarat, Sportech, Bacanora enter black

EARNINGS UPDATES: STV, Chaarat, Sportech, Bacanora enter black

Read more
2 Sep 2021 14:55

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
2 Aug 2021 11:39

TRADING UPDATES: Brickability buys Leadcraft; Aquis has record July

TRADING UPDATES: Brickability buys Leadcraft; Aquis has record July

Read more
2 Aug 2021 11:34

Destiny Pharma reports positive secondary data on 'XF-73'

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced additional, "strong" data from its recent phase 2b clinical trial on Monday.

Read more
6 Jul 2021 20:38

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

TRADING UPDATES: Hipgnosis placing oversubscribed; Creightons delays

Read more
6 Jul 2021 10:35

Destiny Pharma inks research deal with US Veterans' Affairs

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced a cooperative research and development agreement with the US Department of Veterans' Affairs on Tuesday, to support studies focusing on identifying new attributes for 'NTCD-M3' - a novel microbiome therapeutic being developed to reduce the recurrence of Clostridioides difficile infections in the gut.

Read more
10 Jun 2021 19:46

TRADING UPDATES: Ergomed and Dekel Agri-Vision earnings growing

TRADING UPDATES: Ergomed and Dekel Agri-Vision earnings growing

Read more
7 Jun 2021 17:59

TRADING UPDATES: Alba Mineral in Thule asset boost; Nuformix US patent

TRADING UPDATES: Alba Mineral in Thule asset boost; Nuformix US patent

Read more
2 Jun 2021 19:10

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

Read more
2 Jun 2021 10:26

Destiny Pharma reports positive progress on lead clinical programme

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma announced positive progress with its lead clinical programme, 'NTCD-M3', on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.